Alembic Pharma

{
  "main_header": {
    "sid": 807696,
    "name": "Alembic Pharma",
    "stock_name": "Alembic Pharma",
    "full_name": "Alembic Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/alembic-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "761.80",
    "chg": -3.35,
    "chgp": "-0.44%",
    "dir": -1,
    "prev_price": "765.15",
    "mcapval": "14,924.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 533573,
    "symbol": "APLLTD",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE901L01018",
    "curr_date": "Jan 21",
    "curr_time": "",
    "bse_nse_vol": "74.25 k",
    "exc_status": "Active",
    "traded_date": "Jan 21, 2026",
    "traded_date_str": "2026 01 21",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alembic-pharma-807696-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Alembic Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3795861",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AlembicPharmace_mojoScore_3795861.png",
        "date": "2026-01-20 10:10:43",
        "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Why is Alembic Pharmaceuticals Ltd. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-alembic-pharmaceuticals-ltd-fallingrising-3787705",
        "imagepath": "",
        "date": "2026-01-10 01:28:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>The stock has underperformed both its sector and benchmark indices consistently. Over the last week, Alembic Pharmaceuticals has fallen by 4.64%, significantly lagging behind the Sensex’s 2.55% decline. This underperformance extends to the one-month period, where the stock dropped 9.68% compared to the Sensex’s modest 1.29% fall. Year-to-date, the stock has declined by 5.60%, again underperforming the broader market’s 1.93% decrease. Such persistent weakness is compounded by the fact that the stock has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical outlook.</p>\n<p>Investor participation has increased, with delivery volumes on 08 Jan risi..."
      },
      {
        "title": "Alembic Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3786720",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AlembicPharmace_mojoScore_3786720.png",
        "date": "2026-01-09 10:10:44",
        "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Alembic Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3772248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharmace_mojoScore_3772248.png",
        "date": "2025-12-28 10:10:03",
        "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Alembic Pharma Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharma-downgraded-to-sell-by-marketsmojo-amid-weak-financial-trends-3761135",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharma_mojoScore_3761135.png",
        "date": "2025-12-17 10:10:32",
        "description": "Alembic Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued stock performance and sector dynamics."
      },
      {
        "title": "Alembic Pharmaceuticals: Technical Momentum Shifts Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-faces-bearish-momentum-amid-technical-downgrade-3740237",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharmace_technicaldot_3740237.png",
        "date": "2025-12-02 08:08:59",
        "description": "Alembic Pharmaceuticals is currently navigating a phase marked by a discernible shift in technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent assessment changes highlight a transition in key technical indicators, signalling a more cautious outlook for the stock amid broader market fluctuations."
      },
      {
        "title": "Alembic Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-downgraded-to-sell-amid-technical-weakness-and-growth-concerns-3730418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_mojoScore_3730418.png",
        "date": "2025-11-26 08:18:57",
        "description": "Alembic Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results, long-term growth trends, and evolving technical signals have collectively influenced the updated evaluation of its investment profile."
      },
      {
        "title": "Alembic Pharmaceuticals: Technical Momentum Shifts Signal Market Caution",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-faces-mildly-bearish-momentum-amid-technical-downgrade-3730303",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_technicaldot_3730303.png",
        "date": "2025-11-26 08:07:05",
        "description": "Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments indicating a transition from a sideways trend to a mildly bearish stance. This development is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and volume-based metrics, suggesting a nuanced market outlook for the pharmaceutical sector player."
      },
      {
        "title": "How has been the historical performance of Alembic Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-alembic-pharma-3729609",
        "imagepath": "",
        "date": "2025-11-25 22:56:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.</p>\n<p>Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres..."
      }
    ],
    "total": 5257,
    "sid": "807696",
    "stock_news_url": "https://www.marketsmojo.com/news/alembic-pharmaceuticals-807696"
  },
  "announcements": [
    {
      "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled \"Alembic Pharmaceuticals receives USFDA Final Approval for Silodosin Capsules, 4 mg and 8 mg.\".",
      "source": "NSE",
      "caption": "Alembic Pharmaceuticals Limited - Press Release",
      "datetime": "26-Nov-2019"
    },
    {
      "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 22, 2019, titled \"Alembic Pharmaceuticals receives USFDA Approvals \".",
      "source": "NSE",
      "caption": "Alembic Pharmaceuticals Limited - Press Release",
      "datetime": "22-Nov-2019"
    },
    {
      "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ( Listing Regulations, 2015 )",
      "source": "NSE",
      "caption": "Alembic Pharmaceuticals Limited - Other General Purpose",
      "datetime": "14-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "05 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Alembic Pharmaceuticals Ltd. has declared <strong>550%</strong> dividend, ex-date: 29 Jul 25",
          "dt": "2025-07-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-01-20 10:10:43

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Why is Alembic Pharmaceuticals Ltd. falling/rising?

2026-01-10 01:28:01

Recent Price Movement and Market Performance

The stock has underperformed both its sector and benchmark indices consistently. Over the last week, Alembic Pharmaceuticals has fallen by 4.64%, significantly lagging behind the Sensex’s 2.55% decline. This underperformance extends to the one-month period, where the stock dropped 9.68% compared to the Sensex’s modest 1.29% fall. Year-to-date, the stock has declined by 5.60%, again underperforming the broader market’s 1.93% decrease. Such persistent weakness is compounded by the fact that the stock has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical outlook.

Investor participation has increased, with delivery volumes on 08 Jan risi...

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-01-09 10:10:44

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2025-12-28 10:10:03

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Alembic Pharma Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-17 10:10:32

Alembic Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued stock performance and sector dynamics.

Read full news article

Alembic Pharmaceuticals: Technical Momentum Shifts Amid Market Challenges

2025-12-02 08:08:59

Alembic Pharmaceuticals is currently navigating a phase marked by a discernible shift in technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent assessment changes highlight a transition in key technical indicators, signalling a more cautious outlook for the stock amid broader market fluctuations.

Read full news article

Alembic Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-11-26 08:18:57

Alembic Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results, long-term growth trends, and evolving technical signals have collectively influenced the updated evaluation of its investment profile.

Read full news article

Alembic Pharmaceuticals: Technical Momentum Shifts Signal Market Caution

2025-11-26 08:07:05

Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments indicating a transition from a sideways trend to a mildly bearish stance. This development is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and volume-based metrics, suggesting a nuanced market outlook for the pharmaceutical sector player.

Read full news article

How has been the historical performance of Alembic Pharma?

2025-11-25 22:56:06

Revenue and Profit Trends

Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.

Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres...

Read full news article

View All News